Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 21, 2011BloodOpen Access

90Y-Ibritumomab tiuxetan, fludarabine, and TBI-based nonmyeloablative allogeneic transplantation conditioning for patients with persistent high-risk B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAjay K. GopalCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South AfricaKGKatherine A. GuthrieCape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South AfricaJRJoseph G. RajendranUnited States Food and Drug Administration

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Gopal et al. (2011) studied this question.

synapsesocial.com/papers/6a1ef1c708df8bb755b2f64fhttps://doi.org/10.1182/blood-2010-12-324392
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation2007 · 187 citations
  2. 2Recurrence Rates Following Radiation Therapy of Nodular and Diffuse Malignant Lymphomas1973 · 148 citations
  3. 3Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning2005 · 333 citations
  4. 4Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support1993 · 653 citations
  5. 5Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation2002 · 390 citations